Amidst the lung cancer landscape, small cell lung cancer (SCLC) comprises about 15% of the 2.4 million plus patients diagnosed with lung cancer worldwide each year.1-3 SCLC progresses rapidly, with approximately 70% of newly diagnosed patients having extensive-stage disease, meaning the cancer has spread to both lungs and/or beyond the lungs to other parts of the body.4 A diagnosis of SCLC paints a stark picture, as the average 5-year relative survival rate for SCLC is only 7%.5-7 After decades [...]
This is an abstract of the document. To keep reading, click here and get access to the original version.
Disclaimer
Amgen Inc. published this content on
16 May 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
16 May 2024 23:33:01 UTC.